Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3036656 + delamanid
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK3036656 + delamanid is a combination therapy under clinical investigation for the treatment of pulmonary tuberculosis (including drug-sensitive and multidrug-resistant TB). GSK3036656, also known as ganfeborole, is a small molecule inhibitor of *leucyl-tRNA synthetase*, selectively targeting *Mycobacterium tuberculosis*.[2][5] Delamanid is a prodrug in the nitroimidazole class that inhibits mycolic acid synthesis after activation by bacterial nitroreductase.[7] The combination aims to leverage the distinct mechanisms of both agents to enhance bactericidal activity and reduce development of resistance. GSK3036656 has shown safety and efficacy in Phase 1 trials and entered Phase 2 clinical studies.[2][5] Delamanid has received conditional approval for MDR-TB and is used in regimens for resistant tuberculosis.[7][4][1]
- Other names
- GSK3036656 + delamanid
02
Targets
InhALeuRS (Leucyl-tRNA synthetase)
Beyond the preview
Go deeper on GSK3036656 + delamanid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3036656 + delamanid.